Machuca A, Soriano V
Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.
J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):189-93. doi: 10.1097/00126334-200006010-00017.
HTLV-I and HTLV-II infect T lymphocytes. A high HTLV-I proviral load in peripheral blood mononuclear cells (PBMCs) has been associated with a higher risk of neurologic disease. For HTLV-II, large numbers of infected lymphocytes might contribute to accelerate the immunodeficiency and increase the risk of neuropathy in HTLV-II/HIV-1 coinfected people. We have examined the impact of antiretroviral drugs on HTLV proviral load, testing longitudinal samples collected from 1 HTLV-I infected patient suffering HTLV-I-associated myelopathy (HAM), and two HTLV-II/ HIV-1 coinfected subjects. The HAM patient showed a reduction greater than 2 log in the peripheral proviral load after being treated with zidovudine and lamivudine. In contrast, potent antiretroviral treatment in HIV-1/HTLV-II coinfected carriers produced an initial increase in the HTLV proviral load, which was followed by a reduction greater than 1 log thereafter. In conclusion, antiretroviral drugs seem to reduce HTLV proviral load, although in HIV-1 coinfected persons a transient increase in HTLV proviral load could reflect the rapid blocking of HIV-1 replication occurring in response to therapy, thus causing an increase in the number of circulating T lymphocytes carrying HTLV proviral DNA.
人类嗜T淋巴细胞病毒I型（HTLV-I）和人类嗜T淋巴细胞病毒II型（HTLV-II）感染T淋巴细胞。外周血单个核细胞（PBMC）中HTLV-I前病毒载量高与神经疾病风险较高相关。对于HTLV-II，大量受感染的淋巴细胞可能促使免疫缺陷加速，并增加HTLV-II/HIV-1合并感染人群患神经病变的风险。我们检测了抗逆转录病毒药物对HTLV前病毒载量的影响，检测了从1例患有HTLV-I相关脊髓病（HAM）的HTLV-I感染患者以及2例HTLV-II/HIV-1合并感染受试者采集的纵向样本。该HAM患者在接受齐多夫定和拉米夫定治疗后，外周前病毒载量降低超过2个对数。相比之下，HIV-1/HTLV-II合并感染携带者接受强效抗逆转录病毒治疗后，HTLV前病毒载量最初会升高，随后会降低超过1个对数。总之，抗逆转录病毒药物似乎能降低HTLV前病毒载量，尽管在HIV-1合并感染的人群中，HTLV前病毒载量的短暂升高可能反映了因治疗导致HIV-1复制迅速受阻，从而使携带HTLV前病毒DNA的循环T淋巴细胞数量增加。
